Q1 2026 Holdings
Filed 2026-05-14 | 88 holdings | $168.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Alphabet Inc(GOOG) | Common | 02079K107 | $26.2M | 91,420 | 15.6% |
| Apollo Global Management, Inc.(APO) | Common | 03769M106 | $25.1M | 225,000 | 14.9% |
| Syndax Pharmaceutical, Inc.(SNDX) | Common | 87164F105 | $9.9M | 422,000 | 5.9% |
| Bridgebio Pharma, Inc.(BBIO) | Common | 10806X102 | $6.7M | 90,000 | 4.0% |
| Protagonist Therapeutics, Inc(PTGX) | Common | 74366E102 | $6.6M | 63,000 | 4.0% |
| Xeris Biopharma Holdings, Inc.(XERS) | Common | 98422E103 | $6.1M | 1,060,000 | 3.7% |
| JPMorgan Chase & Co.(JPM) | Common | 46625H100 | $5.7M | 19,477 | 3.4% |
| Iovance Biotherapeutics, Inc.(IOVA) | Common | 462260100 | $5.6M | 1,600,000 | 3.3% |
| LPL Financial Holdings Inc. | Common | 52012V100 | $5.0M | 16,500 | 3.0% |
| Janus Henderson AAA CLO ETF(JAAA) | Common | 47103U845 | $4.7M | 93,528 | 2.8% |
| Alkermes PLC(ALKS) | Common | G01767105 | $4.2M | 120,000 | 2.5% |
| Travere Therapeutics, Inc.(TVTX) | Common | 89422G107 | $4.2M | 140,633 | 2.5% |
| Cogent Biosciences Inc.(COGT) | Common | 19240Q201 | $4.0M | 104,000 | 2.4% |
| Viridian Therapeutics, Inc.(VRDN) | Common | 92790C104 | $3.5M | 181,000 | 2.1% |
| Agios Pharmaceutical, Inc.(AGIO) | Common | 00847X104 | $3.1M | 93,058 | 1.9% |
| Relmada Therapeutics, Inc.(RLMD) | Common | 75955J402 | $3.1M | 439,300 | 1.8% |
| TG Therapeutics, Inc.(TGTX) | Common | 88322Q108 | $3.0M | 90,001 | 1.8% |
| Catalyst Pharmaceuticals, Inc.(CPRX) | Common | 14888U101 | $3.0M | 120,000 | 1.8% |
| Arcellx Inc(ACLX) | Common | 03940C100 | $2.2M | 19,433 | 1.3% |
| Spdr S&P Biotech ETF(XBI) | Common | 78464A870 | $1.9M | 15,000 | 1.1% |
| AllianceBernstein Holding L.P.(AB) | Common | 01881G106 | $1.8M | 48,000 | 1.1% |
| Arcus Biosciences, Inc.(RCUS) | Common | 03969F109 | $1.8M | 81,241 | 1.0% |
| DocGo, Inc.(DCGO) | Common | 256086109 | $1.7M | 2,670,850 | 1.0% |
| Cybin Inc(HELP) | Common | 23256X407 | $1.7M | 350,000 | 1.0% |
| Cytokinetics, Incorporated(CYTK) | Common | 23282W605 | $1.6M | 23,644 | 0.9% |
| Centessa Pharmaceuticals PLC(CNTA) | Common | 152309100 | $1.5M | 39,000 | 0.9% |
| AtriCure, Inc.(ATRC) | Common | 04963C209 | $1.5M | 51,400 | 0.9% |
| Ardelyx, Inc.(ARDX) | Common | 039697107 | $1.2M | 207,000 | 0.7% |
| The Panagram Bbb-B CLO ETF(CLOZ) | Common | 81752T528 | $1.2M | 47,807 | 0.7% |
| Johnson & Johnson(JNJ) | Common | 478160104 | $1.2M | 4,922 | 0.7% |
| Rezolute, Inc.(RZLT) | Common | 76200L309 | $1.1M | 370,000 | 0.7% |
| Orchestra Biomed Holdings, Inc.(OBIO) | Common | 68572M106 | $1.1M | 253,651 | 0.6% |
| Madrigal Pharmaaceuticals, Inc.(MDGL) | Common | 558868105 | $1.0M | 2,000 | 0.6% |
| Vera Therapeutics, Inc.(VERA) | Common | 92337R101 | $1.0M | 26,000 | 0.6% |
| Connect Biopharma Holdings Limited(CNTB) | Common | G23549101 | $1.0M | 387,835 | 0.6% |
| iShares Biotechnology ETF(IBB) | Common | 464287556 | $928.7K | 5,500 | 0.6% |
| Pfizer Inc.(PFE) | Common | 717081103 | $908.0K | 32,337 | 0.5% |
| Bristol-Myers Squibb Company(BMY) | Common | 110122108 | $826.2K | 13,622 | 0.5% |
| Canadian Natural Resources Limited(CNQ) | Common | 136385101 | $818.7K | 16,800 | 0.5% |
| Biogen Inc.(BIIB) | Common | 09062X103 | $733.3K | 4,000 | 0.4% |
| Ultragenyx Pharmaceutical Inc.(RARE) | Common | 90400D108 | $692.8K | 33,069 | 0.4% |
| Apple Inc.(AAPL) | Common | 037833100 | $633.0K | 2,494 | 0.4% |
| Microsoft Corporation(MSFT) | Common | 594918104 | $592.3K | 1,600 | 0.4% |
| Verastem Inc.(VSTM) | Common | 92337C203 | $551.2K | 104,000 | 0.3% |
| Adma Biologics, Inc.(ADMA) | Common | 000899104 | $542.4K | 60,200 | 0.3% |
| International Business Machines(IBM) | Common | 459200101 | $519.3K | 2,142 | 0.3% |
| Biohaven Pharmaceutical Holding Co. Ltd(BHVN) | Common | G111OE107 | $513.7K | 60,720 | 0.3% |
| Pelthos Therapeutics, Inc.(PTHS) | Common | 171126204 | $442.7K | 21,073 | 0.3% |
| Kura Oncology, Inc.(KURA) | Common | 50127T109 | $429.0K | 52,767 | 0.3% |
| Evolus, Inc.(EOLS) | Common | 30052C107 | $408.3K | 99,338 | 0.2% |